首页 > 最新文献

Current Opinion in Clinical Nutrition and Metabolic Care最新文献

英文 中文
Amino acids and cancer: potential for therapies? 氨基酸和癌症:治疗的潜力?
IF 3.1 3区 医学 Q1 Medicine Pub Date : 2024-01-01 Epub Date: 2023-11-25 DOI: 10.1097/MCO.0000000000000998
Jéssika M Siqueira, Maria C M Dela Vega, Gustavo D Pimentel

Purpose of review: Cancer patients may have a variety of disorders associated with systemic inflammation caused by disease progression. Consequently, we have protein hypercatabolism. In view of this, protein and amino acid adequacy should be considered in relation to nutritional behavior. Therefore, this review aims to evaluate the influence of protein and amino acids in the nutritional therapy of cancer.

Recent findings: Diets with adequate protein levels appear to be beneficial in the treatment of cancer; guidelines suggest consumption of greater than 1.0-1.5 g/kg body weight/day. In patients diagnosed with malnutrition, sarcopenia, or cachexia, it is recommended to use the maximum amount of protein (1.5 g/kg of weight/day) to adapt the diet. In addition, based on the evidence found, there is no consensus on the dose and effects in cancer patients of amino acids such as branched-chain amino acids, glutamine, arginine, and creatine.

Summary: When evaluating the components of the diet of cancer patients, the protein recommendation should be greater than 1.0-1.5 g/kg of weight/day, with a distribution between animal and vegetable proteins. We found little evidence demonstrating clinical benefits regarding individual or combined amino acid supplementation. Still, it is unclear how the use, dose, and specificity for different types of cancer should be prescribed or at what stage of treatment amino acids should be prescribed.

综述目的:癌症患者可能有多种疾病进展引起的全身性炎症相关疾病。因此,我们有蛋白质高分解代谢。鉴于此,蛋白质和氨基酸的充足性应考虑到营养行为。因此,本文就蛋白质和氨基酸在癌症营养治疗中的作用进行综述。最近的研究发现:含有足够蛋白质水平的饮食似乎对治疗癌症有益;指南建议每日摄入量大于每公斤体重1.0-1.5克。在诊断为营养不良、肌肉减少症或恶病质的患者中,建议使用最大量的蛋白质(1.5 g/kg体重/天)来适应饮食。此外,根据所发现的证据,对支链氨基酸、谷氨酰胺、精氨酸和肌酸等氨基酸对癌症患者的剂量和影响尚无共识。摘要:在评价癌症患者饮食成分时,蛋白质推荐量应大于1.0-1.5 g/kg体重/天,并在动物性蛋白质和植物性蛋白质之间分布。我们发现很少有证据表明单独或联合补充氨基酸有临床益处。然而,对于不同类型的癌症应该如何使用、剂量和特异性,或者在治疗的哪个阶段应该使用氨基酸,目前还不清楚。
{"title":"Amino acids and cancer: potential for therapies?","authors":"Jéssika M Siqueira, Maria C M Dela Vega, Gustavo D Pimentel","doi":"10.1097/MCO.0000000000000998","DOIUrl":"10.1097/MCO.0000000000000998","url":null,"abstract":"<p><strong>Purpose of review: </strong>Cancer patients may have a variety of disorders associated with systemic inflammation caused by disease progression. Consequently, we have protein hypercatabolism. In view of this, protein and amino acid adequacy should be considered in relation to nutritional behavior. Therefore, this review aims to evaluate the influence of protein and amino acids in the nutritional therapy of cancer.</p><p><strong>Recent findings: </strong>Diets with adequate protein levels appear to be beneficial in the treatment of cancer; guidelines suggest consumption of greater than 1.0-1.5 g/kg body weight/day. In patients diagnosed with malnutrition, sarcopenia, or cachexia, it is recommended to use the maximum amount of protein (1.5 g/kg of weight/day) to adapt the diet. In addition, based on the evidence found, there is no consensus on the dose and effects in cancer patients of amino acids such as branched-chain amino acids, glutamine, arginine, and creatine.</p><p><strong>Summary: </strong>When evaluating the components of the diet of cancer patients, the protein recommendation should be greater than 1.0-1.5 g/kg of weight/day, with a distribution between animal and vegetable proteins. We found little evidence demonstrating clinical benefits regarding individual or combined amino acid supplementation. Still, it is unclear how the use, dose, and specificity for different types of cancer should be prescribed or at what stage of treatment amino acids should be prescribed.</p>","PeriodicalId":10962,"journal":{"name":"Current Opinion in Clinical Nutrition and Metabolic Care","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138298621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Casein glycomacropeptide in phenylketonuria: does it bring clinical benefit? 苯丙酮尿症中的酪蛋白糖化肽:它能带来临床益处吗?
IF 3.1 3区 医学 Q1 Medicine Pub Date : 2023-12-14 DOI: 10.1097/MCO.0000000000001000
A. Daly, F. Ilgaz, A. Pinto, Anita MacDonald
Purpose of review Casein glycomacropeptide (CGMP) is a milk-derived bioactive sialyated phosphorylated peptide with distinctive nutritional and nutraceutical properties, produced during the cheese making process. It comprises 20–25% of total protein in whey products. CGMP is low in phenylalanine (Phe) and provides an alternative to Phe-free amino acids as a source of protein equivalent for patients with phenylketonuria (PKU). The amino acid sequence of CGMP is adapted by adding the amino acids histidine, leucine, tyrosine, arginine and tryptophan to enable its suitability in PKU. CGMP has potential antibacterial, antioxidative, prebiotic, remineralizing, digestion /metabolism and immune-modulating properties. The aim of this review is to assess the evidence for the role of CGMP in the management of PKU. Recent findings In PKU, there is no agreement concerning the amino acid composition of CGMP protein substitutes and consequently the nutritional composition varies between products. Although there is evidence in patients or animal models that CGMP has possible beneficial effects on gut microbiota and bone health, the results are inconclusive. Data on kinetic advantage is limited. Most studies report an increase in blood Phe levels with CGMP. Appropriate adaptations and reduction of dietary Phe intake should be made to compensate for the residual Phe content of CGMP, particularly in children. Data from short term studies indicate improved palatability of CGMP when compared to Phe-free amino acids. Summary In PKU, CGMP with supplementary amino acids, offers a safe low Phe nitrogen source. Current scientific evidence is unconvincing about its bioactive advantage in PKU. Further longitudinal research is necessary.
酪蛋白糖大肽(Casein glycomacropeptide, CGMP)是一种源自牛奶的生物活性磷酸化肽,具有独特的营养和营养保健特性,在奶酪制作过程中产生。它占乳清产品中总蛋白质的20-25%。CGMP中苯丙氨酸(Phe)含量低,为苯丙酮尿(PKU)患者提供了一种替代非苯丙氨酸的氨基酸作为蛋白质当量的来源。通过加入组氨酸、亮氨酸、酪氨酸、精氨酸和色氨酸等氨基酸,调整了CGMP的氨基酸序列,使其适合于PKU。CGMP具有潜在的抗菌、抗氧化、益生元、再矿化、消化/代谢和免疫调节特性。本综述的目的是评估CGMP在PKU管理中的作用的证据。在北京大学,对CGMP蛋白质替代品的氨基酸组成没有一致的看法,因此不同产品的营养成分不同。尽管在患者或动物模型中有证据表明CGMP可能对肠道微生物群和骨骼健康有益,但结果尚无定论。关于动力优势的数据有限。大多数研究报告CGMP会增加血液Phe水平。应适当调整和减少膳食Phe摄入量,以补偿CGMP中剩余Phe含量,特别是在儿童中。短期研究的数据表明,与不含phe的氨基酸相比,CGMP的适口性得到了改善。在北京大学,CGMP与补充氨基酸,提供了一个安全的低Phe氮源。目前的科学证据并不足以证明其在北大的生物活性优势。进一步的纵向研究是必要的。
{"title":"Casein glycomacropeptide in phenylketonuria: does it bring clinical benefit?","authors":"A. Daly, F. Ilgaz, A. Pinto, Anita MacDonald","doi":"10.1097/MCO.0000000000001000","DOIUrl":"https://doi.org/10.1097/MCO.0000000000001000","url":null,"abstract":"Purpose of review Casein glycomacropeptide (CGMP) is a milk-derived bioactive sialyated phosphorylated peptide with distinctive nutritional and nutraceutical properties, produced during the cheese making process. It comprises 20–25% of total protein in whey products. CGMP is low in phenylalanine (Phe) and provides an alternative to Phe-free amino acids as a source of protein equivalent for patients with phenylketonuria (PKU). The amino acid sequence of CGMP is adapted by adding the amino acids histidine, leucine, tyrosine, arginine and tryptophan to enable its suitability in PKU. CGMP has potential antibacterial, antioxidative, prebiotic, remineralizing, digestion /metabolism and immune-modulating properties. The aim of this review is to assess the evidence for the role of CGMP in the management of PKU. Recent findings In PKU, there is no agreement concerning the amino acid composition of CGMP protein substitutes and consequently the nutritional composition varies between products. Although there is evidence in patients or animal models that CGMP has possible beneficial effects on gut microbiota and bone health, the results are inconclusive. Data on kinetic advantage is limited. Most studies report an increase in blood Phe levels with CGMP. Appropriate adaptations and reduction of dietary Phe intake should be made to compensate for the residual Phe content of CGMP, particularly in children. Data from short term studies indicate improved palatability of CGMP when compared to Phe-free amino acids. Summary In PKU, CGMP with supplementary amino acids, offers a safe low Phe nitrogen source. Current scientific evidence is unconvincing about its bioactive advantage in PKU. Further longitudinal research is necessary.","PeriodicalId":10962,"journal":{"name":"Current Opinion in Clinical Nutrition and Metabolic Care","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138632994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alternative sources of bioactive omega-3 fatty acids: what are the options? 生物活性欧米加-3 脂肪酸的替代来源:有哪些选择?
IF 3.1 3区 医学 Q1 Medicine Pub Date : 2023-12-08 DOI: 10.1097/mco.0000000000001006
Ella J Baker
The very-long chain (VLC) omega-3 polyunsaturated fatty acids (PUFAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) promote optimal development, physiological function and healthy ageing and help to manage disease. EPA and DHA are sourced mainly from fish, which is not sustainable. This review explores alternative sustainable sources.
超长链(VLC)欧米加-3 多不饱和脂肪酸(PUFAs)二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)可促进最佳发育、生理功能和健康老龄化,并有助于控制疾病。EPA 和 DHA 的主要来源是鱼类,这不是可持续的。本综述探讨了其他可持续来源。
{"title":"Alternative sources of bioactive omega-3 fatty acids: what are the options?","authors":"Ella J Baker","doi":"10.1097/mco.0000000000001006","DOIUrl":"https://doi.org/10.1097/mco.0000000000001006","url":null,"abstract":"The very-long chain (VLC) omega-3 polyunsaturated fatty acids (PUFAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) promote optimal development, physiological function and healthy ageing and help to manage disease. EPA and DHA are sourced mainly from fish, which is not sustainable. This review explores alternative sustainable sources.","PeriodicalId":10962,"journal":{"name":"Current Opinion in Clinical Nutrition and Metabolic Care","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138825809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fluid therapy in diabetic ketoacidosis. 糖尿病酮症酸中毒的液体疗法。
IF 3.1 3区 医学 Q1 Medicine Pub Date : 2023-12-01 DOI: 10.1097/mco.0000000000001005
Mahesh Ramanan, Anthony Delaney, Balasubramanian Venkatesh
To evaluate recent evidence (2021-2023) on fluid therapy in diabetic ketoacidosis. Key evidence gaps which require generation of new evidence are discussed.
评估糖尿病酮症酸中毒液体疗法的最新证据(2021-2023 年)。讨论需要生成新证据的关键证据缺口。
{"title":"Fluid therapy in diabetic ketoacidosis.","authors":"Mahesh Ramanan, Anthony Delaney, Balasubramanian Venkatesh","doi":"10.1097/mco.0000000000001005","DOIUrl":"https://doi.org/10.1097/mco.0000000000001005","url":null,"abstract":"To evaluate recent evidence (2021-2023) on fluid therapy in diabetic ketoacidosis. Key evidence gaps which require generation of new evidence are discussed.","PeriodicalId":10962,"journal":{"name":"Current Opinion in Clinical Nutrition and Metabolic Care","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138825750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Definition, diagnosis, and treatment of respiratory sarcopenia. 呼吸道肌肉疏松症的定义、诊断和治疗。
IF 3.1 3区 医学 Q1 Medicine Pub Date : 2023-11-30 DOI: 10.1097/mco.0000000000001003
Shinjiro Miyazaki, Akira Tamaki, Hidetaka Wakabayashi, Hidenori Arai
Skeletal muscle weakness and wasting also occurs in the respiratory muscles, called respiratory sarcopenia. Respiratory sarcopenia may lead to worse clinical indicators and outcomes. We present a novel definition and diagnostic criteria for respiratory sarcopenia, summarize recent reports on the association between respiratory sarcopenia, physical and nutritional status, and clinical outcomes, and provide suggestions for the prevention and treatment of respiratory sarcopenia.
呼吸肌也会出现骨骼肌虚弱和萎缩,称为呼吸肌疏松症。呼吸肌疏松症可能导致临床指标和预后恶化。我们提出了呼吸道肌肉疏松症的新定义和诊断标准,总结了呼吸道肌肉疏松症、体能和营养状况与临床结果之间关系的最新报告,并对呼吸道肌肉疏松症的预防和治疗提出了建议。
{"title":"Definition, diagnosis, and treatment of respiratory sarcopenia.","authors":"Shinjiro Miyazaki, Akira Tamaki, Hidetaka Wakabayashi, Hidenori Arai","doi":"10.1097/mco.0000000000001003","DOIUrl":"https://doi.org/10.1097/mco.0000000000001003","url":null,"abstract":"Skeletal muscle weakness and wasting also occurs in the respiratory muscles, called respiratory sarcopenia. Respiratory sarcopenia may lead to worse clinical indicators and outcomes. We present a novel definition and diagnostic criteria for respiratory sarcopenia, summarize recent reports on the association between respiratory sarcopenia, physical and nutritional status, and clinical outcomes, and provide suggestions for the prevention and treatment of respiratory sarcopenia.","PeriodicalId":10962,"journal":{"name":"Current Opinion in Clinical Nutrition and Metabolic Care","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138826993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The use of commercial wrist-worn technology to track physiological outcomes in behavioral interventions. 使用商业手腕佩戴技术来跟踪行为干预中的生理结果。
IF 3.1 3区 医学 Q1 Medicine Pub Date : 2023-11-01 Epub Date: 2023-07-26 DOI: 10.1097/MCO.0000000000000970
Ashley L Artese, Rahul Rawat, Anthony D Sung

Purpose of review: The aim of this review is to provide an overview of the use of commercial wrist-worn mobile health devices to track and monitor physiological outcomes in behavioral interventions as well as discuss considerations for selecting the optimal device.

Recent findings: Wearable technology can enhance intervention design and implementation. The use of wrist-worn wearables provides the opportunity for tracking physiological outcomes, thus providing a unique approach for assessment and delivery of remote interventions. Recent findings support the utility, acceptability, and benefits of commercial wrist-worn wearables in interventions, and they can be used to continuously monitor outcomes, remotely administer assessments, track adherence, and personalize interventions. Wrist-worn devices show acceptable accuracy when measuring heart rate, blood pressure, step counts, and physical activity; however, accuracy is dependent on activity type, intensity, and device brand. These factors should be considered when designing behavioral interventions that utilize wearable technology.

Summary: With the continuous advancement in technology and frequent product upgrades, the capabilities of commercial wrist-worn devices will continue to expand, thus increasing their potential use in intervention research. Continued research is needed to examine and validate the most recent devices on the market to better inform intervention design and implementation.

综述目的:本综述的目的是概述商用腕戴移动健康设备在行为干预中跟踪和监测生理结果的用途,并讨论选择最佳设备的考虑因素。最近的发现:可穿戴技术可以增强干预措施的设计和实施。腕戴可穿戴设备的使用为跟踪生理结果提供了机会,从而为评估和提供远程干预提供了一种独特的方法。最近的研究结果支持了商用腕戴可穿戴设备在干预中的实用性、可接受性和益处,它们可用于持续监测结果、远程管理评估、跟踪依从性和个性化干预。在测量心率、血压、步数和体力活动时,手腕佩戴的设备显示出可接受的准确性;然而,准确性取决于活动类型、强度和设备品牌。在设计利用可穿戴技术的行为干预措施时,应考虑这些因素。摘要:随着技术的不断进步和产品的频繁升级,商用腕戴设备的能力将不断扩大,从而增加其在干预研究中的潜在用途。需要继续研究,以检查和验证市场上最新的设备,从而更好地为干预设计和实施提供信息。
{"title":"The use of commercial wrist-worn technology to track physiological outcomes in behavioral interventions.","authors":"Ashley L Artese,&nbsp;Rahul Rawat,&nbsp;Anthony D Sung","doi":"10.1097/MCO.0000000000000970","DOIUrl":"10.1097/MCO.0000000000000970","url":null,"abstract":"<p><strong>Purpose of review: </strong>The aim of this review is to provide an overview of the use of commercial wrist-worn mobile health devices to track and monitor physiological outcomes in behavioral interventions as well as discuss considerations for selecting the optimal device.</p><p><strong>Recent findings: </strong>Wearable technology can enhance intervention design and implementation. The use of wrist-worn wearables provides the opportunity for tracking physiological outcomes, thus providing a unique approach for assessment and delivery of remote interventions. Recent findings support the utility, acceptability, and benefits of commercial wrist-worn wearables in interventions, and they can be used to continuously monitor outcomes, remotely administer assessments, track adherence, and personalize interventions. Wrist-worn devices show acceptable accuracy when measuring heart rate, blood pressure, step counts, and physical activity; however, accuracy is dependent on activity type, intensity, and device brand. These factors should be considered when designing behavioral interventions that utilize wearable technology.</p><p><strong>Summary: </strong>With the continuous advancement in technology and frequent product upgrades, the capabilities of commercial wrist-worn devices will continue to expand, thus increasing their potential use in intervention research. Continued research is needed to examine and validate the most recent devices on the market to better inform intervention design and implementation.</p>","PeriodicalId":10962,"journal":{"name":"Current Opinion in Clinical Nutrition and Metabolic Care","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9889291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Iron regulation and absorption in athletes: contemporary thinking and recommendations. 运动员铁的调节和吸收:当代思考和建议。
IF 3.1 3区 医学 Q1 Medicine Pub Date : 2023-11-01 Epub Date: 2023-07-06 DOI: 10.1097/MCO.0000000000000966
Peter Peeling, Alannah McKay

Purpose of review: This review examines recent developments in our understanding of iron regulation/absorption around exercise, with specific attention paid towards the female athlete.

Recent findings: Building on the well accepted knowledge that hepcidin concentrations increase in the 3-6 h period following an acute bout of exercise, recent studies have shown that this links to a reduced fractional iron absorption from the gut during feedings provided 2 h postexercise. Further, a window of enhanced iron absorption has recently been identified to occur 30 min either side of exercise commencement/completion, which allows for strategic iron intake to optimize absorption around exercise. Finally, there is burgeoning evidence to show that iron status and iron regulation change throughout the menstrual cycle and with hormonal contraceptive use, which could have implications for iron status in female athletes.

Summary: Exercise can affect iron regulatory hormone activity, which subsequently impairs iron absorption, potentially contributing to the high rates of iron deficiency seen in athletes. Future research should continue to examine strategies to optimize iron absorption, with consideration to the timing, mode and intensity of exercise, the time of day, and in females, the menstrual cycle/menstrual status.

综述的目的:本综述考察了我们对运动铁调节/吸收的理解的最新进展,特别关注女运动员。最近的发现:基于公认的铁调素浓度在3-6岁时增加的知识 在剧烈运动后的h期,最近的研究表明,这与喂食期间肠道铁吸收率降低有关。2 h运动后。此外,最近发现了铁吸收增强的窗口30 min运动开始/完成的两侧,这允许战略性地摄入铁,以优化运动前后的吸收。最后,有越来越多的证据表明,铁的状态和铁的调节在整个月经周期和激素避孕药的使用中都会发生变化,这可能会对女运动员的铁状态产生影响。总结:运动会影响铁调节激素的活性,从而损害铁的吸收,可能导致运动员缺铁率高。未来的研究应继续研究优化铁吸收的策略,考虑运动的时间、模式和强度、一天中的时间,以及女性的月经周期/月经状态。
{"title":"Iron regulation and absorption in athletes: contemporary thinking and recommendations.","authors":"Peter Peeling,&nbsp;Alannah McKay","doi":"10.1097/MCO.0000000000000966","DOIUrl":"10.1097/MCO.0000000000000966","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review examines recent developments in our understanding of iron regulation/absorption around exercise, with specific attention paid towards the female athlete.</p><p><strong>Recent findings: </strong>Building on the well accepted knowledge that hepcidin concentrations increase in the 3-6 h period following an acute bout of exercise, recent studies have shown that this links to a reduced fractional iron absorption from the gut during feedings provided 2 h postexercise. Further, a window of enhanced iron absorption has recently been identified to occur 30 min either side of exercise commencement/completion, which allows for strategic iron intake to optimize absorption around exercise. Finally, there is burgeoning evidence to show that iron status and iron regulation change throughout the menstrual cycle and with hormonal contraceptive use, which could have implications for iron status in female athletes.</p><p><strong>Summary: </strong>Exercise can affect iron regulatory hormone activity, which subsequently impairs iron absorption, potentially contributing to the high rates of iron deficiency seen in athletes. Future research should continue to examine strategies to optimize iron absorption, with consideration to the timing, mode and intensity of exercise, the time of day, and in females, the menstrual cycle/menstrual status.</p>","PeriodicalId":10962,"journal":{"name":"Current Opinion in Clinical Nutrition and Metabolic Care","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9761500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Dietary fiber deficiency in individuals with metabolic syndrome: a review. 代谢综合征患者的膳食纤维缺乏:综述。
IF 3.1 3区 医学 Q1 Medicine Pub Date : 2023-11-01 Epub Date: 2023-09-18 DOI: 10.1097/MCO.0000000000000971
Arvind Veluvali, Michael Snyder

Purpose of review: Metabolic syndrome (MetS) refers to a group of risk factors, which increase the risk of cardiovascular disease (CVD), type 2 diabetes (T2D), and other chronic diseases. Dietary fiber has been shown to mitigate many of the effects of various risk factors associated with MetS. Our review summarizes the recent findings on the association between dietary fiber deficiency and MetS.

Recent findings: A number of studies have shown that dietary fiber deficiency is associated with an increased risk of MetS. The main mechanisms by which dietary fiber may reduce the risk of MetS include reduction of cholesterol levels; improvement of blood sugar control; reduction of inflammation; and promotion of weight loss.

Summary: Literature suggests that a deficiency in dietary fiber consumption is a risk factor for MetS. An increase in dietary fiber intake may help to reduce the risk of developing MetS and its associated chronic diseases.

综述目的:代谢综合征(MetS)是指一组增加心血管疾病(CVD)、2型糖尿病(T2D)和其他慢性疾病风险的危险因素。膳食纤维已被证明可以减轻与代谢综合征相关的各种风险因素的许多影响。我们的综述总结了膳食纤维缺乏与代谢综合征之间关系的最新发现。最新发现:许多研究表明,膳食纤维缺乏会增加代谢综合征的风险。膳食纤维降低代谢综合征风险的主要机制包括降低胆固醇水平;改善血糖控制;减少炎症;以及促进减肥。综述:文献表明,膳食纤维摄入不足是代谢综合征的一个危险因素。增加膳食纤维摄入可能有助于降低患代谢综合征及其相关慢性疾病的风险。
{"title":"Dietary fiber deficiency in individuals with metabolic syndrome: a review.","authors":"Arvind Veluvali, Michael Snyder","doi":"10.1097/MCO.0000000000000971","DOIUrl":"10.1097/MCO.0000000000000971","url":null,"abstract":"<p><strong>Purpose of review: </strong>Metabolic syndrome (MetS) refers to a group of risk factors, which increase the risk of cardiovascular disease (CVD), type 2 diabetes (T2D), and other chronic diseases. Dietary fiber has been shown to mitigate many of the effects of various risk factors associated with MetS. Our review summarizes the recent findings on the association between dietary fiber deficiency and MetS.</p><p><strong>Recent findings: </strong>A number of studies have shown that dietary fiber deficiency is associated with an increased risk of MetS. The main mechanisms by which dietary fiber may reduce the risk of MetS include reduction of cholesterol levels; improvement of blood sugar control; reduction of inflammation; and promotion of weight loss.</p><p><strong>Summary: </strong>Literature suggests that a deficiency in dietary fiber consumption is a risk factor for MetS. An increase in dietary fiber intake may help to reduce the risk of developing MetS and its associated chronic diseases.</p>","PeriodicalId":10962,"journal":{"name":"Current Opinion in Clinical Nutrition and Metabolic Care","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41132050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nutritional interventions in prehabilitation for cancer surgery. 癌症手术前康复的营养干预。
IF 3 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-11-01 Epub Date: 2023-08-22 DOI: 10.1097/MCO.0000000000000974
Joshua Wall, Melanie Paul, Bethan E Phillips

Purpose of review: Nutrition remains a key focus in the preoptimization of patients undergoing cancer surgery. Given the catabolic nature of cancer, coupled with the physiological insult of surgery, malnutrition (when assessed) is prevalent in a significant proportion of patients. Therefore, robust research on interventions to attenuate the detrimental impact of this is crucial.

Recent findings: As a unimodal prehabilitation intervention, assessment for malnutrition is the first step, as universal supplementation has not been shown to have a significant impact on outcomes. However, targeted nutritional therapy, whether that is enteral or parenteral, has been shown to improve the nutritional state of patients' presurgery, potentially reducing the rate of postoperative complications such as nosocomial infections. As part of multimodal prehabilitation, the situation is more nuanced given the difficulty in attribution of effects to the differing components, and vast heterogeneity in intervention and patient profiles.

Summary: Multimodal prehabilitation is proven to improve length of hospital stay and postoperative outcomes, with nutrition forming a significant part of the therapy given. Further work is required to look at not only the interplay between the optimization of nutritional status and other prehabilitation interventions, but also how to best select which patients will achieve significant benefit.

综述目的:营养仍然是癌症手术患者预优化的关键焦点。考虑到癌症的分解代谢性质,再加上手术的生理损伤,营养不良(评估时)在很大一部分患者中普遍存在。因此,对干预措施进行强有力的研究以减轻这一不利影响至关重要。最近的研究结果:作为一种单一模式的康复干预措施,营养不良评估是第一步,因为普遍补充营养尚未显示出对结果有重大影响。然而,有针对性的营养治疗,无论是肠内还是肠外,都已被证明可以改善患者术前的营养状态,有可能降低术后并发症(如医院感染)的发生率。作为多模式康复的一部分,考虑到难以将影响归因于不同的组成部分,以及干预和患者档案的巨大异质性,情况更加微妙。综述:多模式康复已被证明可以改善住院时间和术后结果,营养是治疗的重要组成部分。需要进一步的工作,不仅要研究营养状况优化和其他康复干预措施之间的相互作用,还要研究如何最好地选择哪些患者将获得显著的益处。
{"title":"Nutritional interventions in prehabilitation for cancer surgery.","authors":"Joshua Wall, Melanie Paul, Bethan E Phillips","doi":"10.1097/MCO.0000000000000974","DOIUrl":"10.1097/MCO.0000000000000974","url":null,"abstract":"<p><strong>Purpose of review: </strong>Nutrition remains a key focus in the preoptimization of patients undergoing cancer surgery. Given the catabolic nature of cancer, coupled with the physiological insult of surgery, malnutrition (when assessed) is prevalent in a significant proportion of patients. Therefore, robust research on interventions to attenuate the detrimental impact of this is crucial.</p><p><strong>Recent findings: </strong>As a unimodal prehabilitation intervention, assessment for malnutrition is the first step, as universal supplementation has not been shown to have a significant impact on outcomes. However, targeted nutritional therapy, whether that is enteral or parenteral, has been shown to improve the nutritional state of patients' presurgery, potentially reducing the rate of postoperative complications such as nosocomial infections. As part of multimodal prehabilitation, the situation is more nuanced given the difficulty in attribution of effects to the differing components, and vast heterogeneity in intervention and patient profiles.</p><p><strong>Summary: </strong>Multimodal prehabilitation is proven to improve length of hospital stay and postoperative outcomes, with nutrition forming a significant part of the therapy given. Further work is required to look at not only the interplay between the optimization of nutritional status and other prehabilitation interventions, but also how to best select which patients will achieve significant benefit.</p>","PeriodicalId":10962,"journal":{"name":"Current Opinion in Clinical Nutrition and Metabolic Care","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552833/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10058512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic strategies targeting the endothelial glycocalyx. 针对内皮糖盏的治疗策略。
IF 3.1 3区 医学 Q1 Medicine Pub Date : 2023-11-01 Epub Date: 2023-08-09 DOI: 10.1097/MCO.0000000000000973
Daniel R Machin, Mostafa Sabouri, Xiangyu Zheng, Anthony J Donato

Purpose of review: This review will highlight recent studies that have examined the endothelial glycocalyx in a variety of health conditions, as well as potential glycocalyx-targeted therapies.

Recent findings: A degraded glycocalyx is present in individuals that consume high sodium diet or have kidney disease, diabetes, preeclampsia, coronavirus disease 2019 (COVID-19), or sepsis. Specifically, these conditions are accompanied by elevated glycocalyx components in the blood, such as syndecan-1, syndecans-4, heparin sulfate, and enhanced heparinase activity. Impaired glycocalyx barrier function is accompanied by decreased nitric oxide bioavailability, increased leukocyte adhesion to endothelial cells, and vascular permeability. Glycocalyx degradation appears to play a key role in the progression of cardiovascular complications. However, studies that have used glycocalyx-targeted therapies to treat these conditions are scarce. Various therapeutics can restore the glycocalyx in kidney disease, diabetes, COVID-19, and sepsis. Exposing endothelial cells to glycocalyx components, such as heparin sulfate and hyaluronan protects the glycocalyx.

Summary: We conclude that the glycocalyx is degraded in a variety of health conditions, although it remains to be determined whether glycocalyx degradation plays a causal role in disease progression and severity, and whether glycocalyx-targeted therapies improve patient health outcomes. Future studies are warranted to investigate therapeutic strategies that target the endothelial glycocalyx.

综述目的:本综述将重点介绍最近在各种健康状况下检测内皮糖盏的研究,以及潜在的糖盏靶向治疗方法。最近的发现:在高钠饮食或患有肾病、糖尿病、先兆子痫、2019冠状病毒病(新冠肺炎)或败血症的个体中存在糖盏降解。具体而言,这些情况伴随着血液中糖盏组分的升高,如syndecan-1、syndecans-4、硫酸肝素和肝素酶活性的增强。糖盏屏障功能受损伴有一氧化氮生物利用度降低、白细胞与内皮细胞粘附增加和血管通透性增加。糖盏降解似乎在心血管并发症的进展中起着关键作用。然而,使用糖盏靶向疗法治疗这些疾病的研究很少。各种治疗方法可以恢复肾病、糖尿病、新冠肺炎和败血症中的糖盏。将内皮细胞暴露于糖盏组分,如硫酸肝素和透明质酸,可保护糖盏。总结:我们得出的结论是,糖盏在各种健康状况下都会降解,尽管糖盏降解是否在疾病进展和严重程度中起到因果作用,以及糖盏靶向治疗是否能改善患者的健康结果仍有待确定。未来的研究需要研究针对内皮糖盏的治疗策略。
{"title":"Therapeutic strategies targeting the endothelial glycocalyx.","authors":"Daniel R Machin, Mostafa Sabouri, Xiangyu Zheng, Anthony J Donato","doi":"10.1097/MCO.0000000000000973","DOIUrl":"10.1097/MCO.0000000000000973","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review will highlight recent studies that have examined the endothelial glycocalyx in a variety of health conditions, as well as potential glycocalyx-targeted therapies.</p><p><strong>Recent findings: </strong>A degraded glycocalyx is present in individuals that consume high sodium diet or have kidney disease, diabetes, preeclampsia, coronavirus disease 2019 (COVID-19), or sepsis. Specifically, these conditions are accompanied by elevated glycocalyx components in the blood, such as syndecan-1, syndecans-4, heparin sulfate, and enhanced heparinase activity. Impaired glycocalyx barrier function is accompanied by decreased nitric oxide bioavailability, increased leukocyte adhesion to endothelial cells, and vascular permeability. Glycocalyx degradation appears to play a key role in the progression of cardiovascular complications. However, studies that have used glycocalyx-targeted therapies to treat these conditions are scarce. Various therapeutics can restore the glycocalyx in kidney disease, diabetes, COVID-19, and sepsis. Exposing endothelial cells to glycocalyx components, such as heparin sulfate and hyaluronan protects the glycocalyx.</p><p><strong>Summary: </strong>We conclude that the glycocalyx is degraded in a variety of health conditions, although it remains to be determined whether glycocalyx degradation plays a causal role in disease progression and severity, and whether glycocalyx-targeted therapies improve patient health outcomes. Future studies are warranted to investigate therapeutic strategies that target the endothelial glycocalyx.</p>","PeriodicalId":10962,"journal":{"name":"Current Opinion in Clinical Nutrition and Metabolic Care","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10592259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9980542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Opinion in Clinical Nutrition and Metabolic Care
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1